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Abstract. In this study functional magnetic resonance imaging (fMRI) is used to investigate the functional brain activation pattern
in the preclinical stage of AD (pre-AD) subjects during a visual encoding memory task. Thirty subjects, eleven in the pre-AD
stage, with decreased cerebrospinal fluid levels of A42 (<500 pg/ml), and 19 controls with normal A42 levels (CTR) were
included. fMRI was acquired during a visual encoding task. Data were analyzed through an Independent Component Analysis
(ICA) and region-of-interest-based univariate analysis of task-related BOLD signal change. From the ICA decomposition, we
identified the main task-related component, which included the activation of visual associative areas and prefrontal executive
regions, and the deactivation of the default-mode network. The activation was positively correlated with task performance in the
CTR group (p < 0.0054). Within this pattern, subjects in the pre-AD stage had significantly greater activation of the precuneus
and posterior cingulate cortex during encoding. Subjects in the pre-AD stage present distinct functional neural activity before
the appearance of clinical symptomatology. These findings may represent that subtle changes in functional brain activity precede
clinical and cognitive symptoms in the AD continuum. Present findings provide evidence suggesting that fMRI may be a suitable
biomarker of preclinical AD.
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INTRODUCTION
The main pathological lesions in Alzheimer’s dis-
ease (AD) are neurofibrillary tangles and senile plaques
formed by neuronal accumulations of abnormal tau
filaments and extracellular deposits of amyloid fib-
rils. Cerebrospinal fluid (CSF) studies measuring
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amyloid-42 (A42) and tau protein levels in AD
patients with confirmed pathology have demonstrated
that abnormal levels of both biomarkers constitute
a specific signature of the underlying AD-related
pathology [1].
The neuropathological burden of AD occurs very
early during the course of the disease, preceding the
appearance of clinical symptoms [2]. It has been shown
that AD pathology begins a decade before the appear-
ance of symptoms, or in some cases even earlier [2, 3].
Recent studies have demonstrated that approximately
25% of older non-demented individuals have A42
deposition, corroborating the data observed in studies
with postmortem confirmation [4, 5]. The significance
and prognostic value of AD pathological lesions in
cognitively healthy individuals is still under debate.
Some authors hold that these lesions are irrelevant,
while others regard them as part of the pathophysi-
ology of the disease, indicating that these individuals
are at the preclinical stage [6, 7].
Recently, it has been postulated that the preclinical
stage of the disease is a long asymptomatic period dur-
ing which the pathophysiological process progresses.
Subjects in the preclinical stage of AD (pre-AD) have
been defined as individuals who have evidence of early
AD pathological changes but who do not meet clini-
cal criteria for mild cognitive impairment (MCI) or
dementia [8]. Furthermore, individuals with biomarker
evidence of AD are supposed to have an increased risk
for developing cognitive and behavioral impairment
[8]. Two groups have been distinguished within pre-
AD; presymptomatic AD subjects and asymptomatic
at-risk state for AD [9]. Presymptomatic subjects apply
to individuals belonging to rare monogenic AD fami-
lies who will develop AD if they live up until the age of
disease onset in their family; by contrast asymptomatic
at risk do not have a genetically determined risk and can
be identified in vivo by evidence of amyloidosis of the
brain (either through PET or CSF). Furthermore, cog-
nitive performance in this latter group is related with
CSF A42 values [10], suggesting that the preclinical
stage may be different from normal aging. Therefore,
determining brain functional changes in pre-AD sub-
jects may be useful to support the hypothesis that the
preclinical state of AD is distinct from normal aging.
In addition, characterizing the preclinical state from
the perspective of imaging and biomarkers may help
to design future trials with disease-modifying therapies
that target this stage of the disease.
Functional MRI (fMRI) is well suited in order
to study patterns of brain activity. Interestingly, and
particularly based on connectivity analyses, fMRI is
suitable to capture the hypercomplex organization of
the human brain and their subtle dysfunctions before
cognitive alterations become apparent, hence result-
ing in a dynamic and sensitive marker for AD [11].
Converging evidence suggest that cerebral amyloido-
sis in pre-AD phases is associated with structural and
functional changes in the medial parietal areas [12],
considered core regions of the default mode network
(DMN), suggesting that these are key regions of early
brain dysfunction associated to AD process. Sperling
et al. [13] demonstrated that high levels of amyloid
deposition were associated with aberrant DMN activ-
ity, similar to the pattern of dysfunction reported in
AD patients. Although previous studies have described
changes in brain function in healthy subjects with posi-
tive PIB [12–15], there are no fMRI in healthy subjects
with pathological CSF A42 values.
Objectives and hypothesis
The aim of this study was to use fMRI to deter-
mine whether the functional brain activation pattern
during encoding is different among pre-AD subjects,
classified according to the presence of pathological
A42 CSF levels. We hypothesize that pre-AD sub-
jects will present a distinct pattern of activation from
healthy controls during encoding, thus suggesting that
this preclinical state is functionally different from
healthy aging. To our knowledge most of the litera-
ture conducted in subjects with pre-AD characteristics
incorporating fMRI technology has been based in
individuals with evidence of amyloid deposition on
PET imaging and in resting state fMRI investigations
[12, 14, 16] with fewer data obtained during cogni-
tive challenge paradigms [13]. In the present study
and according to the findings derived in these previ-
ous reports we expected that functional abnormalities
mainly in posterior cingulate cortex/precuneus regions
would be apparent during memory encoding in our
pre-AD defined by abnormal concentrations of CSF
biomarkers and that functional alterations would cor-
relate with subsequent memory performance.
MATERIAL AND METHODS
Study population
Thirty subjects were recruited from the Alzheimer’s
disease and other cognitive disorders unit at the Hos-
pital Clinic, Barcelona, Spain. All subjects present
normal cognition and met the following criteria: Mini
Mental State Examination (MMSE) scores above
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24, objective cognitive performance within the nor-
mal range (performance within 1.5 SD) in all tests
from a specific test battery (see below), clinical
dementia rating (CDR) scale score of 0, and no signif-
icant psychiatric symptoms or previous neurological
disease. Pre-AD subjects were defined [9] as cogni-
tively preserved subjects with decreased CSF A42
(<500 pg/ml) levels. 11 pre-AD and 19 controls (CTR),
with normal A42 levels, were included. All subjects
underwent clinical and neuropsychological assess-
ment, magnetic resonance imaging (MRI), and lumbar
puncture (LP). The study was approved by the local
ethics committee and all participants gave written
informed consent prior to enrolment.
Determination of CSF biomarkers
Subjects underwent LP between 9 a.m. and 12 p.m.
Ten 10 mL of CSF was collected. The samples were
centrifuged and stored in polypropylene tubes at
−80◦C within the first hour after extraction. Levels
of A1-42, total tau (t-tau), and phosphorylated tau
at threonine-181 (p-tau) were measured by enzyme-
linked immunosorbent assay kits (Innogenetics, Ghent,
Belgium). A cut off of 500 pg/ml was used to
dichotomize the sample into A-positive and A-
negative subjects [17]. These cut off scores are in
agreement with the internal values of our laboratory
[18].
Neuropsychological and functional assessment
Participants were administered a one-hour neu-
ropsychological battery test by a trained neuropsy-
chologist. The battery included memory, language,
praxis, visual perception and frontal functions assess-
ment. All neuropsychological scores were adjusted for
age and educational level. Normative neuropsycholog-
ical data and the neuropsychological battery have been
described in detail elsewhere [19].
MRI acquisition
Subjects were scanned using a 3T Siemens Magne-
tom Trio Tim (Siemens, Erlangen, Germany) at the
Center for Image Diagnosis of the Hospital Clinic
(CDIC) in Barcelona. During the fMRI protocol, 225
T2*-weighted volumes were acquired (TR = 2000 ms,
TE = 16 ms, 40 slices per volume, slice thick-
ness = 3 mm, voxel size = 1.7 × 1.7 mm, distance fac-
tor = 25%, FOV = 220 mm, matrix size = 128 × 128).
A high-resolution T1-weighted MP-RAGE image was
also acquired (TR = 2300 ms, TE = 2.98 ms, 240 sagit-
tal slices, FOV = 256 mm; matrix size = 256 × 256;
slice thickness = 1 mm).
Encoding fMRI session
The cognitive paradigm consisted in a block design
measuring visual encoding memory adapted from a
previous study by our group [20]. The selected images
were emotionally neutral and were selected accord-
ing to color and form. We used an adaptation of a
visual encoding task previously used by our group
[20]. The task consisted of a 15-block design paradigm
with alternating “fixation”, “repeated”, and “encod-
ing” conditions. The whole encoding fMRI session
lasted 7 minutes and 30 seconds, in which each block
lasted 30 seconds and was repeated five times. The
task started with a ‘fixation’ block, which consisted
of the presentation of a white fixation cross situated
in the center of a black screen. Following this block
the ‘repeated’ condition started, which comprised a
repeated presentation of the same image (10 times).
The encoding phase (‘encoding’ block) consisted of a
presentation of 10 novel pictures, with a total of 50 new
photographs. All stimuli (fixation, repeated, encoding)
were presented for two seconds with an interstimulus
interval of one second. Before entering the scanning,
subjects were told to pay attention to the pictures that
would be appearing in the screen, since they would be
asked about them afterwards, but without specifying
the type of assessment.
Memory testing after fMRI session
Immediately after exiting the scanner, subjects were
tested for their memory of the novel scenes in a two-
alternative forced-choice task in which they had to
decide which picture from a pair of scenes (presented
on the left or right of a computer screen) they had pre-
viously seen. Once the patients pressed the response
button (left or right arrow depending on the position of
the photograph), another pair of images was presented,
with a total of 50 pairs. The photographs were matched
for content (between old and new photographs) dur-
ing the recognition task. Recognition memory was
thus obtained with a maximum score of 50. The side
of presentation on the screen of the encoded pic-
ture was randomized so that the scenes appeared the
same number of times on each side. In addition, the
order of presentation of the encoded pictures was ran-
domized with respect to the encoding phase. All the
images were presented using the Presentation software
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program (version 0.50, Neurobehavioral Systems,
2002; http://www.neurobs.com/) implemented on a
laptop computer.
Independent component analysis of fMRI data
A tensor-ICA (TICA) decomposition of the
fMRI datasets was performed as implemented in
MELODIC [21] version 3.10, part of the FSL software
(http://www.fmrib.ox.ac.uk/fsl/) in order to find com-
mon spatio-temporal patterns of signal oscillations.
First, each fMRI dataset was corrected for motion using
MCFLIRT [22]. Then, nonbrain voxels were removed
using BET [23], spatial smoothing with a gaussian ker-
nel of FWHM = 6.0 mm was applied, and the entire
4D dataset was normalized using the grand mean
intensity. High pass temporal filtering (sigma = 50 s)
was used in order to restrict for task-related tempo-
ral patterns, and 4D sets were finally registered to
the MNI152 template. After this preprocessing, fMRI
analysis of the task was carried out using TICA. With
this procedure, fMRI data is decomposed into a set of
spatio-temporally independent components (IC). Spa-
tial maps of each IC were then thresholded using a
Gaussian/gammamixture model and represented on the
MNI standard template.
MELODIC also performed a post-hoc analysis on
the estimated temporal domain for each component.
A general linear model (GLM) matrix was intro-
duced in order to model the task time-series and to
evaluate components related to each contrast (‘encod-
ing’ > ‘repeated’ images and ‘encoding’ > ‘fixation’).
The main component associated with the encoding
of new images was used to define a set of spherical
regions of interest (ROIs) (of 6 mm radius) centered in
the peaks of the main activated and deactivated brain
areas during the task.
ROI-based study of task-associated brain activity
Task-fMRI data was analyzed using a model-driven
approach as implemented in FMRI Analysis Tool
(FEAT) from FSL. Time-series statistical analysis
was carried out using a GLM approach with local
autocorrelation correction [24]. Three regressors were
used to model the different task blocks (‘encoding’,
‘repeated’, and ‘fixation’), three additional regressors,
modeling their first derivatives were introduced as
nuisance variables. Individual contrast images were
computed from the preprocessed functional data as fol-
lows: encoding > repeated images, encoding > fixation
and fixation > task (‘encoding’ + ‘repeated’ images).
In order to measure task-related changes in BOLD
response, we obtained the % signal change within each
ROIs for each of the contrasts defined above, using
FEATQUERY tool.
The values obtained were compared between groups
with independent samples t-test analysis, performed in
SPSS (Statistical Package for Social Sciences, v.16,
Chicago, IL, USA).
RESULTS
Demographic, clinical, and CSF characteristics
Demographic and clinical characteristics are sum-
marized in Table 1. There were no differences in age
between CTR and pre-AD subjects. Mean and SD of
CSF biomarkers are shown in Table 1. As far as neu-
ropsychological features were concerned, there were
no significant differences between groups on any cog-
nitive test or in the presence of subjective memory
complaints. There were also no differences in the
APOE status between groups (p > 0.05).
Performance on functional magnetic resonance
imaging activation task
Recognition performance on the post scan memory
testing ranged from 60% to 100% accuracy (mean cor-
rect, 81.9%; SD, 11.1%). There were no significant
differences between CTR and pre-AD subjects (82.4%
versus 80.8%). Performance on this test was not corre-
lated with subjects’ age, education, or degree of clinical
impairment, as measured by the CDR-SB (p > 0.05).
fMRI results
The ICA revealed a main task-related compo-
nent which was statistically significant for the novel
images > fixation and for the novel > repeated images
(p < 0.00001 in both cases). The spatial map of this
component (see Fig. 1A) included the activation of the
occipital pole, the lateral occipital cortex, the lingual
gyrus and fusiform gyrus (BA17, 18, 19], as well as
the middle and inferior frontal gyrus and the precen-
tral gyrus (BA6, 9, 46]. It also included task-related
deactivations in areas of the default-mode network [25]
such as the precuneus cortex and cingulate gyrus (BA7,
23, 31), and the angular gyrus, supramarginal gyrus,
and lateral occipital cortex (BA19, 39, 40). The activa-
tion of this component was positively correlated with
task performance only in the CTR group (r = 0.531,
p = 0.016).
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Table 1
Demographic, CSF and neuropsychological differences between CTR and pre-AD
CTR (n = 19) Pre-AD (n = 11)
Mean SD Mean SD t p
Age (Years) 67.0 5.5 71.8 9.3 1.8 n.s
Education (Years) 10.9 4.5 8.5 4.5 1.3 n.s
Gender (% women) 68% 63% 0.8+ n.s
A1-42 670.1 131.5 372.9 93.7 6.8 **
t-tau 356.8 224.8 452.5 566.5 0.6 n.s
p-tau 63.7 30.7 71.7 57.3 0.5 n.s
M@T 46.2 3.2 44.0 5.7 1.2 n.s
MMSE 28.3 1.2 28.1 1.6 0.2 n.s
CERAD learning 19.0 3.3 17.7 2.9 1.2 n.s
CERAD recall 5.7 1.5 5.2 1.9 1.2 n.s
CERAD Recognition 19.2 0.8 18.3 1.6 2.2 n.s
FCSRT- learning 25.8 6.1 21.4 7.9 1.0 n.s
FCSRT-total learning 41.3 7.1 39.5 7.5 0.4 n.s
FCSRT-recall 10.1 1.6 8.7 3.5 0.3 n.s
FCSRT-total recall 14.4 1.4 13.4 2.8 0.4 n.s
Visual memory (CERAD) 8.9 2.1 8.1 2.5 1.6 n.s
Boston Naming Test 52.0 4.0 51.7 5.1 0.8 n.s
Semantic Fluency 18.7 4.6 17.8 5.0 0.1 n.s
PDT 14.0 1.0 14.5 0.5 1.4 n.s
VOSP-letters 19.3 0.9 19.8 0.3 1.1 n.s
CERAD praxis 10.1 1.4 10.3 1.1 0.2 n.s
TMT-A 52.3 18.5 56.2 19.1 0.1 n.s
TMT-B 161.3 80.3 158.4 85.9 0.3 n.s
Verbal Fluency (FAS) 32.6 14.3 26.3 13.2 0.9 n.s
Digit symbol 40.8 20.0 50.2 12.6 1.1 n.s
∗∗p < 0.005; +X2.
CTR: controls; AD: Alzheimer’s disease; MT: Memory alteration test; FCSRT: Free and cued selective
reminding test; PDT: perceptual digital test; TMT-A: trail making test A; TMT-B: trail making test B.
A total number of 9 spherical ROIs were defined
from the spatial map of the IC described above. Six
of them were associated with task-related activations,
and three with task-related deactivations (Fig. 1B
and Table 2). The percent signal change between
the encoding for novel images and the repeated
images in the defined ROIs was calculated in both
controls and pre-AD (Supplementary Table; avail-
able online: http://www.j-alz.com/issues/31/vol31-
3.html#supplementarydata01). We only observed a
significant BOLD response in the pre-AD group com-
pared to CTR within the precuneus and posterior
cingulate cortex ROI (t = 3.12, p = 0.004, Fig. 1C).
There was a tendency for negative correlation between
the activity in the precuneus and posterior cingu-
late cortex during encoding and the task performance
(r = −0.315, p = 0.085). The % of signal change in the
rest of the ROIs was not significantly different in pre-
AD respect to controls.
We also examined other components from the ICA
decomposition and found a secondary pattern that
resulted significant in the post-hoc GLM analysis
between groups. This component was associated with
the task time series (i.e., activated during encoding
blocks) and it was more activated in the pre-AD group
(p < 0.0033 in the post-hoc regression analysis). The
spatial map of the component included regions in the
right insular and fronto-orbital cortices, the lingual
gyrus, and the precuneus (Fig. 2)
DISCUSSION
In this study fMRI was used to investigate the
functional brain activation pattern in pre-AD subjects
during a visual encoding memory task. The main task-
related component, found in all subjects (CTR and
pre-AD), included the activation of visual associative
areas and prefrontal executive regions and the deac-
tivation of the default-mode network. An observed
relevant finding was that pre-AD subjects presented
a greater BOLD response scores compared to CTR
within the precuneus and posterior cingulate cortex
ROI during fixation, with a tendency for negative
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Fig. 1. A) Spatial map of the main independent component associated with the encoding condition. Positive (activated) areas are shown in
red-yellow colors and negative (deactivated areas) in blue. B) Spherical ROIs created from the map above. C) Boxplot showing the mean
activation (averaged BOLD response) in the precuneus and posterior cingulate cortex (PCC) for the two groups during encoding.
correlation between the activity in the precuneus and
posterior cingulate cortex during encoding and the task
performance.
The precuneus is a core region of the DMN [26]
included in the posteromedial cortex, which has also
been demonstrated to be a part of a memory sys-
tem that is deactivated during successful encoding
and activated during successful retrieval processes
[27, 28]. The changes we have observed in this
region are prior to the appearance of observable mem-
ory decline in our pre-AD subjects. These results
corroborate results described subtle functional changes
during resting state in healthy subjects with posi-
tive PIB [12–15]. Recently, in a study of cognitively
preserved subjects Sheline et al. [12] found that the
PIB+group differed significantly from the PIB-group
in terms of functional connectivity in the precuneus
to hippocampus, parahippocampus, anterior cingulate,
dorsal cingulate, gyrus rectus, superior precuneus,
and visual cortex during resting state in fMRI. Also,
Sperling et al. [13] demonstrated that high levels
of amyloid deposition were associated with aberrant
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Table 2
Definition and localization of ROIs for fMRI analysis
ROI id Functional network MNI coordinates Brain area
L-OCC Task-positive (–10, –98, 4) Left occipital cortex
L-MFG Task-positive (–54, –6, 40) Left middle frontal gyrus
R-OCC Task-positive (14, –98, 16) Right occipital cortex
R-MFG Task-positive (54, 14, 36) Right middle frontal gyrus
R-IFG Task-positive (50, 38, 12) Right inferior frontal gyrus
R-SFG Task-positive (42, 2, 56) Right superior frontal gyrus
PPC Task-negative (–2, –66, 36) Precuneus/posterior cingulate cortex
L-LOC Task-negative (–46, –58, 40) Left lateral occipital cortex
R-LOC Task-negative (42, –62, 36) Right lateral occipital cortex
L-OCC: left occipital cortex; L-MFG: left middle frontal gyrus; R-OCC: right occipital cortex;
R-MFG: right middle frontal gyrus; R-IFG: right inferior frontal gyrus; R-SFG: right superior
frontal gyrus; PPC: precuneus and posterior cingulate cortex; L-LOC: left lateral occipital cortex;
R-LOC: right lateral occipital cortex.
Fig. 2. Spatial map of the second component found from the independent component analysis decomposition.
default network fMRI activity, similar to the pattern of
dysfunction reported in AD patients. Taking together,
structural and functional changes in the precuneus
and posterior cingulate cortex described in pre-AD
subjects suggest that cerebral amyloidosis in pre-AD
phases is associated with structural and functional
changes in the medial parietal areas, core regions of
the DMN [8, 26]. In this line, recent findings using
cross neuroimaging modality analyses in PIB positive
healthy elders and MCI patients, confirmed that low
metabolism in posterior cingulate cortex/precuneus
regions related to reduced whole-brain connectivity
measured with fMRI, suggesting that these cortical
hub regions may be particularly vulnerable to neu-
rodegeneration induced by elevated amyloid burden
[16].
Taking together, current results and results from pre-
vious studies, may suggest that functional neocortical
changes, mainly in the medial parietal regions occur in
the preclinical phases of the disease while functional
temporal dysfunction have consistently described in
the clinical phases of AD [29, 30]. The fact that neo-
cortical dysfunctions may be present before medial
temporal lobe dysfunction in the AD continuum should
be consolidated by future studies.
We observed hyperactivity in the precuneus and
posterior cingulate cortex in the pre-AD group. In
our sample, although there were no differences in the
recognition task between CTR and pre-AD subjects,
pre-AD subjects activated additional brain resources
in order to perform at the same level as controls.
Therefore, the greater BOLD response within pre-
cuneus and posterior cingulate cortex region found in
the pre-AD subjects during fixation presented a ten-
dency for negative correlation between the activity in
the precuneus and posterior cingulate cortex during
encoding and the task performance. Therefore, more
hyperactivation is associated with high performance
during the task. A hypothesis of hyperactivity regions
during fMRI has been proposed by Sperling et al.
[13], who speculated that the hyperactivity of some
regions could be due to a decrease in synaptic inhi-
bition, potentially modifying the functional properties
of the neurons themselves, rendering them hyperac-
tive. However, further data will be necessary in order
to confirm if this neuron reaction it can be similar to the
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hyperactivity described in some regions like hip-
pocampus, that might represent evidence of neuronal
excitotoxicity, representing impending synaptic failure
and incipient cognitive decline processing [31, 32].
As AD pathology begins decades before the
manifestation of symptoms [8], diagnosis in the
presymptomatic stage may become a reality. This
has intensified the search for efficient preclinical AD
biomarkers. The AD-modifying treatments developed
in the future may well require very early diagnosis
to optimize their potential benefits, and in order to
show their efficacy future trials may have to target a
population with a biological signature of the disease
with minimal or even zero clinical symptomatology
[33]. Although there is currently no consensus on the
significance and prognostic value of AD pathologi-
cal hallmarks detected in the preclinical state, recent
studies from our group suggest that this phase may
be clinically silent but “biologically” active, since
the findings indicate structural MRI changes in both
presymptomatic and pre-AD subjects without cogni-
tive impairment [6, 7]. We now extend this observation
by showing distinct brain functional activity in pre-
AD subjects. How long CSF A42 decrease needs to
be present before brain circuitry change occurs is an
important topic that should be investigated in longi-
tudinal studies. Furthermore, longitudinal studies will
be important to determine the time course of functional
and structural brain changes in order to help plan the
optimal timing for potential interventional studies in
pre-AD individuals.
Some limitations should be considered in our study,
mainly the fact that sample size is relatively small,
due to the difficulties for including this type of sub-
jects; however the main results survived a correction
for multiple comparisons, making them more reliable.
Also, we are aware that the methodology proposed in
this study is exploratory and further studies with larger
sample would be needed for obtaining confirmatory
results about this group. Lack of longitudinal follow-up
is other limitation of this work that has been acknowl-
edged. In this sense, we want to emphasize that the time
period to have sufficient power to detect a conversion
to a dementia of the Alzheimer type (or even to MCI
diagnosis) is very long. However, several studies have
already shown that subjects with positive biomarker
have more likely cognitive impairment and structural
changes after several months of follow-up [34–37]. In
this sense, although individually there is no assurance
the development of dementia in these subjects, the risk
of developing AD in this group is high. Therefore,
we believe that cross-sectional studies as this one will
continue to be necessary, in order to bring new hypoth-
esis to the field.
In summary, our results show that pre-AD subjects
presented increased activation in the precuneus and
posterior cingulate cortex suggests that these are key
regions of early brain dysfunction in the preclinical
AD phases. These findings may represent that subtle
changes in functional brain activity precede clinical
and cognitive symptoms in the AD continuum. The
potential value of fMRI as a biomarker of the preclin-
ical AD state still needs to be demonstrated.
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